Argenx
ARGX
#442
Rank
A$79.75 B
Marketcap
A$1,281
Share price
-3.07%
Change (1 day)
28.88%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): A$13.55

According to Argenx 's latest financial reports the company's current EPS (TTM) is A$13.35. In 2024 the company made an earnings per share (EPS) of A$20.95 an increase over its 2023 EPS that were of A-$7.77.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$13.55-35.34%
2024A$20.95-369.77%
2023A-$7.77-60.46%
2022A-$19.6463.33%
2021A-$12.02-40.37%
2020A-$20.17183.47%
2019A-$7.11123.09%
2018A-$3.1954.93%
2017A-$2.0614.07%
2016A-$1.8013.05%
2015A-$1.60-36.34%
2014A-$2.51209.04%
2013A-$0.81-33.99%
2012A-$1.23185.59%
2011A-$0.43